Asia Pacific Pharmaceutical Contract Research Organization (CRO) 麻豆原创 2020-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity

Publication ID:

GRM1220020

Publication Date:

December 29, 2020

Pages:

112

Publisher:

Grace 麻豆原创 Data

Countries:

Asia Pacific [1]

USD 2,800.00

Pharmaceutical Manufacturing [2]

Drug Delivery [3]

Pharma & Healthcare [4]

Description:

Asia Pacific pharmaceutical CRO market will grow by 9.6% annually with a total addressable market cap of $238.7 billion over 2020-2030 owing to the rising incidence of disease, rising healthcare expenditures, increasing dependence on contract research organizations due to improved efficiency and productivity.
Highlighted with 33 tables and 44 figures, this 112-page report 鈥淎sia Pacific Pharmaceutical Contract Research Organization (CRO) 麻豆原创 2020-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire Asia Pacific pharmaceutical CRO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical CRO market in every aspect of the classification from perspectives of Service, Therapeutic Application, End User, and Country.

Based on Service, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� CRO for Pre-clinical Development
鈥� CRO for Phase I Trials
鈥� CRO for Phase II Trials
鈥� CRO for Phase III Trials
鈥� CRO for Phase IV Trials
鈥� Laboratory Services
鈥� Consulting Services
鈥� Data Management Services

Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Infectious Diseases
鈥� Oncology
鈥� Metabolic Disorders
鈥� Cardiovascular Disorders
鈥� Central Nervous System
鈥� Respiratory Disorders
鈥� Gastrointestinal Disorders
鈥� Other Therapeutic Applications

Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Pharmaceutical & Biopharmaceutical Companies
鈥� Medical Device Companies
鈥� Academic Institutes

Geographically, the following national/local markets are fully investigated:
鈥� Japan
鈥� China
鈥� South Korea
鈥� Australia
鈥� India
鈥� Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Service, Therapeutic Application, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific pharmaceutical CRO market are assayed quantitatively and qualitatively through GMD鈥檚 Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Asia Pacific Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

Table of Contents
1 Introduction 6
1.1 Industry Definition and Research Scope 6
1.1.1 Industry Definition 6
1.1.2 Research Scope 7
1.2 Research Methodology 10
1.2.1 Overview of 麻豆原创 Research Methodology 10
1.2.2 麻豆原创 Assumption 11
1.2.3 Secondary Data 11
1.2.4 Primary Data 11
1.2.5 Data Filtration and Model Design 13
1.2.6 麻豆原创 Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 麻豆原创 Overview and Dynamics 19
2.1 麻豆原创 Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the 麻豆原创 23
2.2 Major Growth Drivers 25
2.3 麻豆原创 Restraints and Challenges 30
2.4 Emerging Opportunities and 麻豆原创 Trends 33
2.5 Porter鈥檚 Fiver Forces Analysis 37
3 Segmentation of Asia Pacific 麻豆原创 by Service 41
3.1 麻豆原创 Overview by Service 41
3.2 CRO for Pre-clinical Development 43
3.3 CRO for Phase I Trials 44
3.4 CRO for Phase II Trials 45
3.5 CRO for Phase III Trials 46
3.6 CRO for Phase IV Trials 47
3.7 Laboratory Services 48
3.8 Consulting Services 49
3.9 Data Management Services 50
4 Segmentation of Asia Pacific 麻豆原创 by Therapeutic Application 51
4.1 麻豆原创 Overview by Therapeutic Application 51
4.2 Infectious Diseases 53
4.3 Oncology 54
4.4 Metabolic Disorders 55
4.5 Cardiovascular Disorders 56
4.6 Central Nervous System 57
4.7 Respiratory Disorders 58
4.8 Gastrointestinal Disorders 59
4.9 Other Therapeutic Applications 60
5 Segmentation of Asia Pacific 麻豆原创 by End User 61
5.1 麻豆原创 Overview by End User 61
5.2 Pharmaceutical & Biopharmaceutical Companies 63
5.3 Medical Device Companies 64
5.4 Academic Institutes 65
6 Asia-Pacific 麻豆原创 2019-2030 by Country 67
6.1 Overview of Asia-Pacific 麻豆原创 67
6.2 Japan 70
6.3 China 73
6.4 Australia 75
6.5 India 77
6.6 South Korea 80
6.7 Rest of APAC Region 82
7 Competitive Landscape 84
7.1 Overview of Key Vendors 84
7.2 New Product Launch, Partnership, Investment, and M&A 88
7.3 Company Profiles 89
Charles River Laboratories 89
CMIC Co. Ltd 91
Covance Inc. 92
Hangzhou Tigermed Consulting Co Ltd 93
ICON Plc 94
IQVIA Holdings Inc. 95
LSK Asia Pacific Pharma Service Co Ltd 96
Novotech Pty Ltd 97
PAREXEL International Corporation 98
Pharmaceutical Product Development LLC (PPD) 99
PRA Health Sciences Inc. 100
Quanticate Ltd 101
Samsung Bioepis Co. Ltd 102
SGS SA (SGS Life Sciences) 103
Syneos Health Inc. 104
WuXi AppTec Inc. 105
8 Investing in Asia Pacific 麻豆原创: Risk Assessment and Management 106
8.1 Risk Evaluation of Asia Pacific 麻豆原创 106
8.2 Critical Success Factors (CSFs) 109
Related Reports and Products 112

Companies Mentioned:

Key Players (this may not be a complete list and extra companies can be added upon request):
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.